Sorbe B, Hallén C
Department of Gynecologic Oncology, Orebro Medical Center, Sweden.
Gynecol Oncol. 1989 Aug;34(2):141-4. doi: 10.1016/0090-8258(89)90129-7.
In a prospective, randomized, double-blind trial the combination betamethasone-dixyrazine was compared with high-dose metoclopramide as antiemetic treatment during combination chemotherapy (melphalan-doxorubicin and cisplatin) of ovarian carcinoma. Of 40 evaluable patients, 15 (38%) had previous experience with chemotherapy. Efficacy and side effects were recorded on patient and nurse questionnaires using the visual analog scale. Nausea and vomiting were prevented in 55% of the patients treated with melphalan-doxorubicin (Day 1) and in 36% of the patients treated with cisplatin (Day 2). Betamethasone-dixyrazine was superior to high-dose metoclopramide and prevented nausea in 76% compared to 32% during melphalan-doxorubicin therapy. Akathisia was noted in 21% and acute dystonic reactions in 2.6% during metoclopramide treatment but not in any case during betamethasone-dixyrazine therapy.
在一项前瞻性、随机、双盲试验中，将倍他米松 - 地昔帕明联合用药与大剂量甲氧氯普胺作为卵巢癌联合化疗（美法仑 - 阿霉素和顺铂）期间的止吐治疗进行了比较。40例可评估患者中，15例（38%）曾接受过化疗。使用视觉模拟量表，通过患者和护士问卷记录疗效和副作用。接受美法仑 - 阿霉素治疗的患者（第1天）中，55%的患者恶心和呕吐得到预防；接受顺铂治疗的患者（第2天）中，36%的患者恶心和呕吐得到预防。倍他米松 - 地昔帕明优于大剂量甲氧氯普胺，在美法仑 - 阿霉素治疗期间，预防恶心的比例为76%，而甲氧氯普胺为32%。甲氧氯普胺治疗期间，21%的患者出现静坐不能，2.6%的患者出现急性肌张力障碍反应，而倍他米松 - 地昔帕明治疗期间未出现任何此类情况。
